Welcome to our dedicated page for TuHURA Biosciences, Inc./NV SEC filings (Ticker: HURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TuHURA Biosciences, Inc./NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TuHURA Biosciences, Inc./NV's regulatory disclosures and financial reporting.
TuHURA Biosciences, Inc. (HURA) reports an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility provides up to $50 million of loan availability and matures on April 21, 2031.
On August 20, 2026, the company drew an additional $650,000 and expects to use these funds for general corporate purposes. The lender is an affiliate of the company’s largest stockholder, and TuHURA highlights risks related to conditions for future drawdowns, sufficiency of available funds, and potential conflicts of interest.
TuHURA Biosciences, Inc. (HURA) reported results of its 2026 Annual Meeting and the approval of equity issued in connection with an existing credit facility. Stockholders approved issuing 1,878,287 common shares to Parkview Holdings One LLC as “Loan Fee Shares” under a previously agreed $50 million revolving credit facility, relying on private placement exemptions for an accredited investor.
Six directors were elected to serve until the 2027 annual meeting. An advisory vote approved named executive officer compensation, and stockholders indicated a preference for conducting future say-on-pay votes every three years. Cherry Bekaert LLP was ratified as independent auditor for the year ending December 31, 2026. A quorum was present, with 43,034,024 of 63,682,528 outstanding shares represented.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing three main technologies, led by IFx-2.0, an innate immune agonist in a Phase 3 registration trial for Merkel cell carcinoma using the FDA’s accelerated approval pathway. The company is also preparing a Phase 1b/2 trial for TBS-2025, a VISTA-inhibiting antibody for mutNPM1 acute myeloid leukemia, and advancing Delta Opioid Receptor–targeted ADCs.
For the six months ended June 30, 2026, TuHURA reported a net loss of $16.8 million and no product revenue, driven mainly by $11.9 million in research and development and $4.4 million in general and administrative expenses. Cash used in operating activities was $13.0 million. As of June 30, 2026, the company had $1.0 million in cash and cash equivalents, total assets of $31.7 million, and an accumulated deficit of $157.9 million.
Liquidity is supported by a new $50 million revolving credit facility with Parkview, of which $3.6 million had been drawn by June 30 and approximately $5.8 million by mid-August 2026, plus an at-the-market equity program and prior equity offerings. Management expects existing capital resources, together with anticipated credit facility drawdowns, to fund planned operations into the end of 2028.
TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, reported second quarter 2026 results and a corporate update focused on advancing IFx-2.0, TBS-2025 and MDSC inhibitor ADC programs. The company highlighted multiple expected milestones through 2027, including prospective orphan drug designations and key trial initiations and readouts.
TuHURA reported cash and cash equivalents of $1.0 million as of June 30, 2026, and noted access to a recently announced $50 million term credit facility from its largest shareholder, described as non-convertible and expected to extend its cash runway into 2028. The facility bears 12% annual interest, with interest paid monthly and principal due at maturity on April 21, 2031, and can be drawn as needed to fund clinical and operating expenses.
For the quarter, research and development expenses were $6.6 million versus $4.9 million a year earlier, mainly from increased clinical activity, while general and administrative expenses were $2.1 million versus $1.9 million, driven in part by non-cash stock compensation and public company costs. Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period, partially offset by $10.6 million of net cash from financing activities. Common shares outstanding were approximately 63.7 million at June 30, 2026.
TuHURA Biosciences, Inc. reported an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The Loan Agreement provides for a maximum loan availability of $50 million and matures on April 21, 2031.
On August 7, 2026, the company drew an additional $650,000 under this facility and expects to use the funds for general corporate purposes. The company notes risks related to its ability to continue drawing under the Loan Agreement and whether available funds will meet its operational and development needs.
TuHURA Biosciences, Inc. reports the creation of a direct financial obligation through an additional borrowing under its existing Loan Agreement with Parkview Holdings One LLC. The agreement provides for a revolving credit facility with a maximum availability of $50 million, maturing on April 21, 2031.
On July 28, 2026, the company drew an additional $1,500,000 under this facility and expects to use the proceeds for general corporate purposes. Management highlights risks related to its ability to meet conditions for future drawdowns, the sufficiency of available funds, and potential conflicts of interest because the lender is an affiliate of the company’s largest stockholder.
TuHURA Biosciences, Inc. is calling a virtual 2026 annual stockholders’ meeting on August 18, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of June 26, 2026, when 63,682,528 common shares were outstanding, may vote online.
Key items include electing six directors, approving under Nasdaq Listing Rule 5635(d) the issuance of 1,878,287 common shares tied to a fee letter with Parkview Holdings One LLC, advisory votes on executive pay and its future frequency, and ratifying Cherry Bekaert LLP as auditor for 2026.
The proxy describes a majority‑independent board with audit, compensation, and nominating committees, a clawback policy, and an insider trading policy. For 2025, CEO James Bianco received total compensation of $3,987,095 and CFO Dan Dearborn received $1,832,036, combining salary, bonuses and equity awards.
TuHURA Biosciences, Inc. has increased its borrowing under an existing revolving credit facility. The company drew an additional $1,900,000 on June 30, 2026, from a loan agreement with Parkview Holdings One LLC that provides up to $50 million in availability and matures on April 21, 2031.
The new funds are expected to be used for general corporate purposes. The filing also highlights risks that the company may not always meet conditions to draw or maintain the loan and notes that the lender is an affiliate of its largest stockholder, which could create potential conflicts of interest.
TuHURA Biosciences, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. Stockholders will vote on election of six directors, ratification of auditors, advisory votes on executive compensation and frequency, and a Nasdaq-related issuance approval of 1,878,287 shares.
Holders of record as of June 26, 2026 are entitled to vote; shares outstanding were 63,682,528 shares as of that record date. The Board unanimously recommends voting FOR the director nominees and the proposals listed in the proxy.